Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled adaptive dose-ranging study of secukinumab (AIN457) in relapsing multiple sclerosis
2012-004019-29Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in multiple sclerosis (MS) (4 arms), sponsored by Novartis. Primary endpoint: Cumulative number of new gadolinium-enhancing T1-weighted MRI lesions. Started Oct 2012; status: terminated.
02
Drugs
secukinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-004019-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004019-29.